Vitamin D status during pregnancy and in cord blood in a large prospective French cohort.

Marie Courbebaisse, Jean-Claude Souberbielle, Amandine Baptiste, Joëlle Taieb, Vassilis Tsatsaris, Jean Guibourdenche, Marie-Victoire Senat, Hazar Haidar, Jacques Jani, Meriem Guizani, et al.

Vitamin D status during pregnancy and in cord blood in a large prospective French cohort.

Authors: Marie Courbebaisse[a]*, Jean-Claude Souberbielle[b], Amandine Baptiste[c], Joëlle Taieb[d], Vassilis Tsatsaris[e,f], Jean Guibourdenche[g], Marie-Victoire Senat[h], Hazar Haidar[i], Jacques Jani[j], Meriem Guizani[j], Jean-Marie Jouannic[k], Marie-Clotilde Haguet[l], Norbert Winer[m], Damien Masson[n], Caroline Elie[c], Alexandra Benachi[e,o]

Affiliations:

[a.] Department of Physiology, Georges Pompidou European Hospital, AP-HP, Université Paris Descartes, INSERM U1151-CNRS UMR8253, Paris, France

[b.] Department of Physiology, Necker-Enfants Malades Hospital, AP-HP, Paris, France

[c.] URC/CIC Paris Descartes Necker Cochin, Necker-Enfants Malades Hospital, AP-HP, Paris, France

[d.] Department of Biochemistry, Antoine-Béclère Hospital, AP-HP, Université Paris-Sud, Clamart, France

[e.] Fondation PremUp, Paris, France

[f.] Department of Obstetrics, Cochin Hospital, AP-HP, Université René Descartes, Paris, France

[g.] Department of Hormonal Biochemistry, Cochin Hospital, AP-HP, Université René Descartes, Paris, France

[h.] Department of Obstetrics and Gynecology, Bicêtre Hospital, AP-HP, Université Paris-Sud, Kremlin Bicêtre, France

[i.] Department of Molecular Genetics, Pharmacogenetics and Hormonology, Bicêtre Hospital, AP-HP, Université Paris-Sud, Kremlin Bicêtre, France

[j.] Department of Obstetrics and Gynecology, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium

[k.] Fetal Medecine Department, Armand Trousseau Hospital, UPMC-Sorbonne Université, Paris, France

[l.] Department of Biochemistry, Armand Trousseau Hospital, UPMC-Sorbonne Université, Paris, France

[m.] Department of Obstetrics and Gynecology, Nantes University Hospital, 44000, France

[n.] Department of Biochemistry, Nantes University Hospital Hôtel-Dieu, Nantes 44000, France

[o.] Department of Obstetrics and Gynecology, Antoine-Béclère Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Sud, Clamart, France

***Corresponding author:**

Marie Courbebaisse, MD, PhD

Department of Physiology, Unit of renal functional explorations

Georges Pompidou European Hospital

20 rue Leblanc, 75015, Paris, France

Tel: +33 1 56 09 39 73

Fax: +33 1 56 09 26 75

Email: marie.courbebaisse@aphp.fr

Abstract:

Background & Aims: Vitamin D status during pregnancy and in newborns has never been studied in France. This study aims at determining the vitamin D status during the first and third trimesters of pregnancy (T1, T3) and in cord blood (CB) in the middle-north of France.

Methods: We conducted a prospective cohort study in five French centers (latitude 47.22 to 48.86°N). Serum 25(OH)-vitamin D (25(OH)D) concentrations were measured using a radioimmunoassay during T1, T3 and in CB. According to the French guidelines, pregnant women received cholecalciferol, 100,000 IU, in the seventh month.

Results: Between April 2012 and July 2014, 2832 women were included, of whom 2803 were analyzed (mean±SD age: 31.5±5.0 years; phototypes 5-6: 21.8%). Three and 88.6% of participants received supplementation during the month before inclusion and in the seventh month, respectively. At T1, T3, and CB, mean 25(OH)D concentrations were 21.9±10.4, 31.8±11.5, and 17.0±7.2 ng/mL, respectively, and 25(OH)D was <20 ng/mL in 46.5%, 14.0%, and 68.5%, respectively. At T1, body mass index ≥25 kg/m^2, dark phototypes, sampling outside summer, and no supplementation before inclusion were independently associated with vitamin D insufficiency (25(OH)D<20ng/mL). Women who received cholecalciferol supplementation in month 7 had higher 25(OH)D at T3 than non-supplemented women (32.5±11.4 *versus* 25.8±11.4 ng/mL, p=<0.001) and marginally higher 25(OH)D in CB (17.2±7.2 *versus* 15.5±7.1 ng/mL, p=0.004).

Conclusions: Despite the recommended supplementation, vitamin D insufficiency is frequent during pregnancy and in newborns in France.

Keywords: Vitamin D; Pregnancy; Newborns; Epidemiology; Supplementation

INTRODUCTION

Vitamin D is a prohormone with effects beyond the prevention of rickets/osteomalacia. In addition to its protective effect against bone demineralization, vitamin D sufficiency is associated with a reduced risk of many chronic diseases including type 2 diabetes mellitus, cardiovascular diseases, cancers, and auto-immune and infectious diseases (1). During pregnancy, poor vitamin D status is associated with pregnancy complications such as pre-eclampsia (2,3), gestational diabetes mellitus (4), and increased risk of caesarean section (5) and of preterm birth (6,7). It is also associated with an increased risk of wheezing and asthma (8,9), of respiratory tract infections (10) and of low bone mass (11,12) in newborns and children.

The assessment of vitamin D status is based on the measurement of the serum concentration of 25(OH)-vitamin D (25(OH)D). During pregnancy, free 25(OH)D might reflect better the vitamin D status than total 25(OH)D due to the rise of vitamin D protein levels (13). Although there is a consensus to define vitamin D deficiency as serum 25(OH)D below 10 ng/mL (25 nmol/L), the definition of vitamin D insufficiency is less consensual. Whereas the US Institute of Medicine (IOM) defines vitamin D insufficiency as serum 25(OH)D concentrations below 20 ng/mL (50 nmol/L) in the general population (14), the Endocrine Society considers 25(OH)D levels below 30 ng/mL (75 nmol/L) to be inadequate in chronically ill patients (15). With low contemporary sun exposure and/or use of sunscreens, the relative contribution of the solar source to total basal input of vitamin D seems to be at best of 25%, the remaining coming from food sources (16). Regardless of the threshold for vitamin D insufficiency or inadequacy, prevalence of low serum 25(OH)D concentrations is high in most countries, including France, in all age groups (17).

Vitamin D status during pregnancy or in cord blood has been evaluated in studies conducted in North America (18,19) and in many European countries, mainly northern Europe, although

few studies have measured 25(OH)D throughout the pregnancy or in cord blood in large cohorts (20–22). Considering i) the high prevalence of vitamin D deficiency or insufficiency during pregnancy reported in most of these studies, ii) the potential deleterious consequences of low 25(OH)D circulating levels on health of both mother and child, and iii) the absence of uniform guidelines for vitamin D supplementation in pregnant women, there is an urgent need to assess vitamin D status in large populations of pregnant women and newborns and, for each country, to systematically evaluate recommendations for vitamin D supplementation during pregnancy. To our best knowledge, such a study has never been conducted in France. That's why we felt important to gather national data given the particularity of the French recommendation for vitamin D supplementation during pregnancy (23) and the lack of food fortification in France.

The aims of the present study were to determine the vitamin D status and its evolution in a large cohort of pregnant women living in France by analysis in the first and third trimesters and in cord blood. We sought to assess the determinants of vitamin D status at each time point and to study the impact of the French recommendations regarding vitamin D supplementation during pregnancy. To answer these questions, we used the prospective observational FEPED cohort study including pregnant women first seen during the first trimester in five centers of the middle-north of France.

PATIENTS AND METHODS

Study protocol

The FEPED study was initially designed to investigate the association of vitamin D status during pregnancy with pre-eclampsia in six centers (five French and one Belgian). Written informed consent was obtained from each patient before inclusion in the study. The protocol was conducted in accordance with the Declaration of Helsinki and was approved by a local

132 independent Ethics Committee (2011/13NICB). It is registered with the ClinicalTrials.gov
133 (identifier NCT01648842). Samples were stored in the Perinat Collection (ANR-10-EQPX-
134 0010).
135
136 For the purpose of the present epidemiological study, which aimed to determine the 25(OH)D
137 status of pregnant women living in France and in their newborns (in cord blood), we did not
138 include women recruited in Bruxelles (Belgium). The patients included in this study were
139 recruited between April 2012 and July 2014 in five French maternity departments ensuring
140 the obstetrical follow-up from the first trimester of pregnancy until delivery. Four of these
141 departments are located in Paris area (Béclère, Bicêtre, Cochin, and Trousseau University
142 hospitals, latitude 48.86°N) and one is located in Nantes in the mid-western part of France
143 (latitude 47.22°N). Patients were told about the study by the obstetrician or the midwife
144 during the first consultation for pregnancy follow-up if the following inclusion and exclusion
145 criteria were fulfilled. Inclusion criteria were: age ≥18 years, single pregnancy, gestational
146 age from 10 to <15 weeks of amenorrhea (WA), corresponding to 8 to <13 gestational weeks
147 (GW), at inclusion, and healthcare coverage. Exclusion criteria were conditions for which
148 vitamin D level could have been modified or vitamin D supplementation during the third
149 trimester could have been contra-indicated or inefficient, including serum calcium levels
150 >2.65 mmol/L or other known pathologies of mineral metabolism, constitutive bone disease,
151 history of urinary stones, lithium treatment, or intestinal malabsorption, and conditions
152 susceptible to interfere with the diagnosis of pre-eclampsia, including uncontrolled
153 hypertension (>140/90 mm Hg from the beginning of pregnancy) and renal insufficiency
154 (serum creatinine >120 µmol/L). For all included patients, a blood sample was collected for
155 25(OH)D measurement between 11 and 14 WA, or between 9 and 12 GW, (the first
156 trimester, T1, sample), during the third trimester (between 28 WA, or 26 GW, and delivery,

157 the T3 sample) and from cord blood (CB) within the framework of the research protocol. The
158 patients were not required to fast before blood sample collection. Vitamin D (100,000 IU of
159 cholecalciferol) was prescribed to all women in the seventh month of pregnancy as a routine
160 procedure in agreement with the French guidelines (23). At obstetrics clinic from 28 GW the
161 patient was asked whether and when she took the vitamin D supplementation and the date was
162 recorded in the patient file. Follow-up outcomes were recorded such as outcome at birth (live
163 birth, per partum demise, termination of pregnancy), gestational age at delivery, birth weight,
164 vitamin D status in the first, third trimester and cord blood.
165 We defined vitamin D deficiency, insufficiency, inadequacy, and sufficiency as serum
166 25(OH)D concentrations of <10 ng/mL, <20 ng/mL, <30 ng/mL, and ≥30 ng/mL,
167 respectively. The phototype of each subject was determined according to the Fitzpatrick skin
168 type classification (24). Pre-pregnancy body mass index (BMI) calculated from height and
169 pre-pregnancy weight was classified using the WHO cut-off for overweight (<25 or ≥25
170 kg/m^2) (25).
171 ***Biological analysis***
172 All blood samples were centrifuged and stored locally at -20°C and were subsequently
173 transferred monthly to the Department of Physiology of Necker University Hospital (Paris,
174 France) for centralized 25(OH)D measurement from serum. 25(OH)D was measured with the
175 DiaSorin radioimmunoassay (RIA). The Necker Hospital Physiology Laboratory participates
176 in the DEQAS proficiency control with excellent results. A value of 4 ng/mL, corresponding
177 to the limit of quantification that we determined in our laboratory, was assigned to any
178 undetectable concentration.
179 ***Statistical analyses***
180 All statistical analyses were undertaken using R 2.11.1 software. Statistical tests were two-
181 sided and p values less than 0.05 were considered statistically significant. Baseline

characteristics of women were described as means ± standard deviations for quantitative variables and frequencies (%) for qualitative variables.

Prevalence of vitamin D insufficiency and inadequacy (serum 25(OH)D concentrations <20 ng/ml and <30 ng/ml respectively) were estimated on the available samples at each time (T1, T3, and CB) along with their corresponding 95% Wald CI.

Associations between characteristics of women and 25(OH)D insufficiency were investigated using chi-squared test (or Fisher's test when it was appropriate) for qualitative factors and Student's t test for quantitative parameters. Pearson's r and p value of its test were computed to examine correlations between continuous variables. Multiple logistic regression models were performed to assess determinants of 25(OH)D insufficiency at T1 and T3 and in CB. Initial models included all significant factors identified by univariate analysis ($p < 0.05$). A backward selection procedure based on likelihood ratio tests was used. Odds ratios, 95% CI, and p values of determinants in the final models were computed.

RESULTS

Description of the study and of the study population

The flow chart of the study protocol is shown in Figure 1. None of the patients were included twice during the study. Among the 2658 women with available data regarding pregnancy outcomes, pregnancies were terminated as follows: 2621 (98.6%) live births, six (0.2%) newborn deaths during labor, 10 (0.4%) in utero deaths, and 21 (0.8%) medical abortions. The mean delivery term was 37.5±1.8 GW.

Figure 1: Flow chart of the study protocol. 25(OH)D: 25(OH)-vitamin D, D: day, T1: first trimester, T3: third trimester, CB: cord blood, GW: gestational weeks. *25(OH)D

measurements performed for women at a term ≥13 GW+0D at the time of T1 sampling were excluded from the analysis.



Characteristics of the cohort are shown in Table 1. Among the 2779 women with available data regarding ethnical origin, 1550 (55.8%) patients originated from Continental France, 63 (2.3%) from northern Europe, 122 (4.4%) from southern Europe, 420 (15.1%) from northern Africa, 292 (10.5%) from Sub-Saharan Africa, 116 (4.2%) from French West Indies, 105 (3.8%) from Asia, and 111 (4%) from other countries. Of note, most women received vitamin D after inclusion in agreement with the French national guidelines.

Evolution of vitamin D status during pregnancy and in cord blood

Mean serum 25(OH)D concentrations for all women with available samples at each time point are presented in Table 2. Vitamin D deficiency (25(OH)D <10 ng/mL) was present in more

221 than 10% of cases during the first trimester and a cord blood but was nearly absent during the
222 third trimester. As shown in Figure 2, around half of the women had vitamin D insufficiency
223 (25(OH)D <20 ng/mL) during the first trimester but only 14% had vitamin D insufficiency
224 during the third trimester. Vitamin D inadequacy (25(OH)D <30 ng/mL) was found in three-
225 quarters of women during the first trimester and was present in nearly half of women during
226 the third trimester. Of note, vitamin D insufficiency or inadequacy was highly prevalent in
227 newborns based on our cord blood analyses.
228
229 **Figure 2.** Prevalence of 25(OH)-vitamin D (25(OH)D) insufficiency (serum 25(OH) D <20
230 ng/mL, red line) and inadequacy (serum 25(OH)D <30 ng/mL, blue line) at the first and third
231 trimesters (T1 and T3) and in cord blood (CB) (with 95% confidence interval). N= number of
232 patients for whom serum 25(OH)D measurements were performed at T1, T2 and T3.



233
234

Serum 25(OH)D significantly increased between the first and the third trimesters among the 2289 women with serum 25(OH)D measurements available at these two visits (22.2±10.5 ng/mL *versus* 31.8±11.5 ng/mL, respectively, with a mean difference of 9.5±12.8 ng/mL, p<0.001). Serum 25(OH)D significantly decreased between the third trimester and cord blood among the 1606 women with serum 25(OH)D measurements available at these two visits (31.7±11.5 ng/mL *versus* 17.1±7.3 ng/mL respectively, with a mean difference of -14.7±8.9 ng/mL, p< 0.001). Figure 3a shows that serum 25(OH)D during the third trimester positively correlates with serum 25(OH)D during the first trimester. Figure 3b shows that the positive correlation between serum 25(OH)D during the third trimester and in cord blood is even stronger.

Figure 3. a: Correlation between serum 25(OH)-vitamin D (25(OH)D) at the first trimester (T1) and at the third trimesters (T3) for the 2289 women with serum 25(OH)D measurements at T1 and at T3. **b:** Correlation between serum 25(OH)D at T3 and in cord blood (CB) for the 1606 women with serum 25(OH)D measurements at T3 and at CB.



(a) (b)

253
254

255 ***Determinants of vitamin D status during pregnancy and in newborns***

256 Univariate analysis of determinants of vitamin D insufficiency (25(OH)D <20 ng/mL) during
257 pregnancy and in cord blood is summarized in Table 3. Table 4 shows 25(OH)D
258 concentrations and categories among women who received or did not receive the
259 recommended supplementation during the seventh month of pregnancy. Vitamin D
260 supplementation during the seventh month did not significantly influence the presence of
261 vitamin D insufficiency in cord blood (Table 3). However, serum 25(OH)D was slightly but
262 significantly higher in cord blood in case of vitamin D supplementation during the seventh
263 month of pregnancy (Table 4). Moreover, there was less vitamin D deficiency (25(OH)D <10
264 ng/mL) in cord blood in supplemented women (Table 4)).

265 Supplementation had a significant impact on serum 25(OH)D concentration during the third
266 trimester since there was virtually no vitamin D deficiency during the third trimester in
267 supplemented women (Table 4). Of note, 11.6% and 41.8% of the supplemented women had
268 vitamin D below 20 or 30 ng/mL, respectively, during the third trimester.

269 Weight gain during pregnancy was not associated with vitamin D insufficiency during the
270 third trimester (+8.7±5.0 kg in the 308 women with serum 25(OH)D <20 ng/mL *versus*
271 +8.5±4.3 kg in the 1908 women with serum 25(OH)D ≥ 20 ng/mL, p= 0.54).

272 Table 5 shows variables independently associated with serum 25(OH)D concentration <20
273 ng/mL during pregnancy and in cord blood. In multivariate analysis, overweight before
274 pregnancy, dark phototype, sampling during fall, winter, or spring, and absence of vitamin D
275 supplementation at the very beginning of pregnancy were independently associated with
276 vitamin D insufficiency in the first trimester. In the third trimester, age below 35 years, parity
277 ≥1, dark phototype, sampling during fall, winter, or spring, absence of vitamin D
278 supplementation during pregnancy, and presence of vitamin D insufficiency or deficiency in

the first trimester were independently associated with vitamin D insufficiency. Vitamin D insufficiency in newborns was independently associated with overweight before pregnancy, sampling during fall, winter, or spring, and presence of vitamin D insufficiency or deficiency in the third trimester.

DISCUSSION

We report the first large scale population cohort study describing serum 25(OH)D status during pregnancy and in cord blood in French women. Given the disparities in results from vitamin D studies conducted during pregnancy world-wide, we will compare our results to those from other European studies.

As highlighted in table 6, during early or mid-pregnancy in countries of northern Europe, serum 25(OH)D levels are relatively low with a mean or median value around 20 to 22 ng/mL, as in our study (20,21,26–28). In the two studies with serum 25(OH)D values above 30 ng/mL despite the high latitudes (Finland and northwest of England) (29,30), a large proportion of women received vitamin D supplementation (95% in the Finland study and 73% in England study). Moreover, there are vitamin D food fortification policies in Finland (31); thus, in the Finnish study the mean vitamin D intake was 15.7 µg/day (29). Mean vitamin D intake for the French general population is 2.3 µg/day (32), a value that can be extrapolated to French pregnant women before the third trimester in the absence of vitamin D supplementation and of food fortification policies in France. Low vitamin D levels are also frequently found in pregnant women in countries from southern Europe despite theoretically higher and more efficient UVB radiation (33). The close values between northern and southern European countries may be explained by high consumption of fatty fish in northern European countries and by vitamin D food fortification policies in some countries (31,33), but also by less voluntary sun exposure and by darker phototype in southern Europe.

We observed a clear increase in serum 25(OH)D concentrations between the first and third trimester. Our results must be interpreted taking into account the vitamin D supplementation currently recommended in France (100,000 IU of cholecalciferol during the seventh month) (23). Consequently, 25(OH)D levels were overall higher in our study during the third trimester than levels reported in most European studies (table 6) (26,27,33,34).

We observed a dramatic decrease in 25(OH)D levels between the third trimester and sampling of cord blood. As observed in previous studies, 25(OH)D levels were approximately two-fold lower in cord blood than in mother's serum during pregnancy (20–22,30,35). In our study, as in these previous studies, sampling in the mother was performed several weeks before delivery. By contrast, in two studies with maternal sampling performed at delivery, exactly at the same time as cord blood sampling, 25(OH)D concentrations in mothers were similar to the ones found in newborns (34,36). This finding suggests that the decrease in serum 25(OH)D observed between the second or third trimesters and cord blood may be due to a rapid decrease in serum 25(OH)D concentrations between sampling and delivery. Possible explanations for this rapid decrease in 25(OH)D levels during the last 4 weeks of pregnancy (mean delay between the third trimester and cord blood samplings in our study) in the absence of further supplementation could be reduced outdoor activity and sun exposure combined with an increase in fat mass at the end of pregnancy. Another explanation could be the rapid decrease in serum 25(OH)D concentrations after the single administration of 100,000 IU of vitamin D_3, as recently described (37). Another hypothesis to explain the discrepancy between 25(OH)D levels in mothers during the second or third trimesters and in newborns could be that 3-epi-25(OH)D_3, an isoform not detected by the current immunoassays, may be present at high concentrations in cord blood. However, this theory was ruled out by a study showing that the proportion of 25(OH)D as 3-epi-25(OH)D_3 was only 11.2% in cord blood (22) and by another study reporting similar levels of 3-epi-25(OH)D_3 in mothers at delivery and in

329 newborns (36). We would like to emphasize that our study demonstrates that this high dose
330 of cholecalciferol given once, 100 000 IU theoretically corresponding to 1100 IU daily during
331 3 months (23), is clearly insufficient to obtain serum 25(OH)D levels above 20 ng/mL in most
332 newborns and is also insufficient to completely prevent vitamin D deficiency.
333 Finally, we analyzed the determinants of vitamin D insufficiency (25(OH)D <20 ng/mL) at
334 each time point. Most studies found, as we did, that season of sampling was strongly
335 associated with 25(OH)D status during pregnancy, with maximal concentrations reached
336 during summer (20,26–28,30,33,38). As in our study, dark phototype was also reported to be
337 independently associated with maternal vitamin D status (26,27,30,33,39). As in other
338 European studies (20,26–28,30,33), we found that vitamin D supplementation during
339 pregnancy was a strong independent determinant of vitamin D status. Whereas some studies
340 found no association between BMI and vitamin D status in pregnant women (27,34), others
341 found, like us, a negative association (40,41) .
342 Few European studies have described the determinants of vitamin status in cord blood. A
343 study from Scotland (20) and a study from Ireland (22), found, like us, that seasonal variation
344 and maternal 25(OH)D status were independently associated with 25(OH)D levels in cord
345 blood. Whereas the study from Scotland (20) found, as we did, that vitamin D
346 supplementation during pregnancy did not influence vitamin D insufficiency in cord blood,
347 two studies (22,29), reported a positive association between antenatal vitamin D supplements
348 and vitamin D concentrations in cord blood. Finally, unlike us, others did not find that
349 maternal BMI was an independent determinant of 25(OH)D levels in cord blood (20,22,29).
350 We must acknowledge that our study has some limitations. First, although the DiaSorin RIA
351 used to measure 25(OH)D concentration in our study is a “historic” 25(OH)D assay that has
352 been used in many studies, it does not allow a strict comparison with the previously published
353 data on vitamin D status in pregnant women due to a certain degree of inter-method

variability. Such a comparison is, however, important to develop evidence-based international guidelines for vitamin D supplementation during pregnancy. A way to achieve this goal would have been to collaborate with a laboratory that uses a CDC-certified chromatography tandem-mass spectrometry (LC-MS/MS) method in order to apply the VDSP protocols for standardizing existing 25(OH)D data from national surveys around the world (42). However, when the present study was designed (in 2009), the new international and the standard LC-MS/MS reference method for measuring 25(OH)D were not published so such a collaboration was not possible. Moreover, we did not assess the concentration of the biologically active free 25(OH)D. Of note, Patients were recruited only in centers from the middle-north of France, so we cannot extrapolate our results to the whole French territory. Finally, some data susceptible to modify serum 25(OH)D concentration including dietary habits, sun exposure, use of sunscreen and outdoor activity were not recorded in the present study.

Our study also has several strengths. To our best knowledge, it is the first study to evaluate the vitamin D status of a French cohort during pregnancy and in cord blood and this study is the largest European study regarding this issue. We also evaluated the effects of the supplementation recommended by current French guidelines (23), which is of high importance to improve the care of pregnant women and newborns.

In conclusion, vitamin D insufficiency is highly prevalent at the beginning of pregnancy and in cord blood in the middle-north of France. The supplementation with cholecalciferol 100,000 IU during the seventh month of pregnancy is insufficient to prevent vitamin D insufficiency and deficiency in newborns and should therefore be reevaluated.

Acknowledgments:

We would like to thank S. Albert, V. Buth, V. da Costa, S. Larrède, E. Etienne, L. Peaudecerf, and I. Rieger for monitoring the data, and A. Bellino and M. Delattre for coordinating the study. We are grateful to the participating doctors, midwives, and nurses for patient

management. We would also like to thank the “Centre de Ressources Biologiques”, Centre Hospitalier Intercommunal de Créteil, for the management and storage of biospecimens. We also thank the patients for their help in making this trial a success.

Statement of Authorship:

MC interpreted the data and wrote the manuscript.

ABa and CE analyzed and interpreted the data.

ABe, CE and JCS conceived and designed the study.

JCS performed 25(OH)D measurements.

JT, VT, JG, MVS, HH, JJ, MG, JMJ, MCH, NW, and DM included patients.

All the authors contributed substantially to the acquisition of data and to drafting the article or revising it critically for important intellectual content and to final approval of the version to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Conflict of Interest Statement:

JC. Souberbielle reports lecture fees and/or travel/hotel expenses from DiaSorin, Roche Diagnostics, Abbott, Amgen, Shire, MSD, Lilly, and Rottapharm/Meda. The other authors declare no conflicts of interest.

Funding sources:

401 The study was sponsored by the Assistance Publique-Hôpitaux de Paris (AP-HP) and was
402 funded by a grant from the Programme Hospitalier de Recherche Publique – PHRC national
403 2010 (Ministry of Health – AOM10113).

404

405

406

407

408

409 **References**

410

411 1. Wacker M, Holick MF. Vitamin D - effects on skeletal and extraskeletal health and the
412 need for supplementation. Nutrients. 10 janv 2013;5(1):111‑48.

413 2. Bodnar LM, Simhan HN, Catov JM, Roberts JM, Platt RW, Diesel JC, et al. Maternal
414 Vitamin D Status and the Risk of Mild and Severe Preeclampsia: Epidemiology. mars
415 2014;25(2):207‑14.

416 3. Mirzakhani H, Litonjua AA, McElrath TF, O'Connor G, Lee-Parritz A, Iverson R, et
417 al. Early pregnancy vitamin D status and risk of preeclampsia. J Clin Invest. 14 nov
418 2016;126(12):4702‑15.

419 4. Lu M, Xu Y, Lv L, Zhang M. Association between vitamin D status and the risk of
420 gestational diabetes mellitus: a meta-analysis. Arch Gynecol Obstet. mai 2016;293(5):959‑66.

421 5. Scholl TO, Chen X, Stein P. Maternal vitamin D status and delivery by cesarean.
422 Nutrients. 2012;4(4):319‑30.

423 6. Miliku K, Vinkhuyzen A, Blanken LM, McGrath JJ, Eyles DW, Burne TH, et al.
424 Maternal vitamin D concentrations during pregnancy, fetal growth patterns, and risks of
425 adverse birth outcomes. Am J Clin Nutr. 1 juin 2016;103(6):1514‑22.

7. Amegah AK, Klevor MK, Wagner CL. Maternal vitamin D insufficiency and risk of adverse pregnancy and birth outcomes: A systematic review and meta-analysis of longitudinal studies. Nguyen TV, éditeur. PLOS ONE. 17 mars 2017;12(3):e0173605.

8. Christesen HT, Elvander C, Lamont RF, JøRgensen JS. The impact of vitamin D in pregnancy on extraskeletal health in children: a systematic review: Impact of vitamin D in pregnancy on children. Acta Obstet Gynecol Scand. déc 2012;91(12):1368‑80.

9. Camargo CA, Ingham T, Wickens K, Thadhani R, Silvers KM, Epton MJ, et al. Cord-blood 25-hydroxyvitamin D levels and risk of respiratory infection, wheezing, and asthma. Pediatrics. janv 2011;127(1):e180-187.

10. Fried DA, Rhyu J, Odato K, Blunt H, Karagas MR, Gilbert-Diamond D. Maternal and cord blood vitamin D status and childhood infection and allergic disease: a systematic review. Nutr Rev. 2016;74(6):387‑410.

11. Dror DK, King JC, Fung EB, Van Loan MD, Gertz ER, Allen LH. Evidence of associations between feto-maternal vitamin D status, cord parathyroid hormone and bone-specific alkaline phosphatase, and newborn whole body bone mineral content. Nutrients. 2012;4(2):68‑77.

12. Zhu K, Whitehouse AJ, Hart PH, Kusel M, Mountain J, Lye S, et al. Maternal Vitamin D Status During Pregnancy and Bone Mass in Offspring at 20 Years of Age: A Prospective Cohort Study: MATERNAL 25OHD IN PREGNANCY AND OFFSPRING BONE MASS AT 20 YEARS OLD. J Bone Miner Res. mai 2014;29(5):1088‑95.

13. Tsuprykov O, Buse C, Skoblo R, Haq A, Hocher B. Reference intervals for measured and calculated free 25-hydroxyvitamin D in normal pregnancy. J Steroid Biochem Mol Biol. juill 2018;181:80‑7.

14. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Dietary Reference Intakes for Calcium and Vitamin D [Internet]. Ross AC, Taylor CL, Yaktine AL, Del Valle HB, éditeurs. Washington (DC): National Academies Press (US); 2011 [cité 12 févr 2018]. (The National Academies Collection: Reports funded by National Institutes of Health). Disponible sur: http://www.ncbi.nlm.nih.gov/books/NBK56070/

15. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. juill 2011;96(7):1911‑30.

16. Heaney RP, Armas LAG, French C. All-source basal vitamin D inputs are greater than previously thought and cutaneous inputs are smaller. J Nutr. mai 2013;143(5):571‑5.

17. Souberbielle J-C, Massart C, Brailly-Tabard S, Cavalier E, Chanson P. Prevalence and determinants of vitamin D deficiency in healthy French adults: the VARIETE study. Endocrine. août 2016;53(2):543‑50.

18. Bodnar LM, Simhan HN, Powers RW, Frank MP, Cooperstein E, Roberts JM. High prevalence of vitamin D insufficiency in black and white pregnant women residing in the northern United States and their neonates. J Nutr. févr 2007;137(2):447‑52.

19. Woolcott CG, Giguère Y, Weiler HA, Spencer A, Forest J-C, Armson BA, et al. Determinants of vitamin D status in pregnant women and neonates. Can J Public Health Rev Can Sante Publique. 27 déc 2016;107(4‑5):e410‑6.

20. Haggarty P, Campbell DM, Knox S, Horgan GW, Hoad G, Boulton E, et al. Vitamin D in pregnancy at high latitude in Scotland. Br J Nutr. 14 mars 2013;109(5):898‑905.

21. Kiely ME, Zhang JY, Kinsella M, Khashan AS, Kenny LC. Vitamin D status is associated with uteroplacental dysfunction indicated by pre-eclampsia and small-for-gestational-age birth in a large prospective pregnancy cohort in Ireland with low vitamin D status. Am J Clin Nutr. août 2016;104(2):354‑61.

22. Kiely M, O'Donovan SM, Kenny LC, Hourihane JO, Irvine AD, Murray DM. Vitamin D metabolite concentrations in umbilical cord blood serum and associations with clinical characteristics in a large prospective mother-infant cohort in Ireland. J Steroid Biochem Mol Biol. 2017;167:162‑8.

23. RPC [Internet]. [cité 27 févr 2018]. Disponible sur: http://www.cngof.fr/pratiques-cliniques/recommandations-pour-la-pratique-clinique?folder=RPC%2BCOLLEGE

24. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. juin 1988;124(6):869‑71.

25. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1‑452.

26. Vandevijvere S, Amsalkhir S, Van Oyen H, Moreno-Reyes R. High prevalence of vitamin D deficiency in pregnant women: a national cross-sectional survey. PloS One. 2012;7(8):e43868.

27. Bärebring L, Schoenmakers I, Glantz A, Hulthén L, Jagner Å, Ellis J, et al. Vitamin D Status during Pregnancy in a Multi-Ethnic Population-Representative Swedish Cohort. Nutrients. 22 oct 2016;8(10).

28. Bjørn Jensen C, Thorne-Lyman AL, Vadgård Hansen L, Strøm M, Odgaard Nielsen N, Cohen A, et al. Development and validation of a vitamin D status prediction model in Danish pregnant women: a study of the Danish National Birth Cohort. PloS One. 2013;8(1):e53059.

29. Hauta-Alus HH, Holmlund-Suila EM, Rita HJ, Enlund-Cerullo M, Rosendahl J, Valkama SM, et al. Season, dietary factors, and physical activity modify 25-hydroxyvitamin D concentration during pregnancy. Eur J Nutr. 2 mars 2017;

30. Emmerson AJB, Dockery KE, Mughal MZ, Roberts SA, Tower CL, Berry JL. Vitamin D status of White pregnant women and infants at birth and 4 months in North West England: A cohort study. Matern Child Nutr. janv 2018;14(1).

31. Spiro A, Buttriss JL. Vitamin D: An overview of vitamin D status and intake in Europe. Nutr Bull. déc 2014;39(4):322‑50.

32. ENNS : étude nationale nutrition santé / Enquêtes et études / Nutrition et santé / Maladies chroniques et traumatismes / Dossiers thématiques / Accueil [Internet]. [cité 13 févr 2018]. Disponible sur: http://invs.santepubliquefrance.fr/Dossiers-thematiques/Maladies-chroniques-et-traumatismes/Nutrition-et-sante/Enquetes-et-etudes/ENNS-etude-nationale-nutrition-sante

33. Karras S, Paschou SA, Kandaraki E, Anagnostis P, Annweiler C, Tarlatzis BC, et al. Hypovitaminosis D in pregnancy in the Mediterranean region: a systematic review. Eur J Clin Nutr. sept 2016;70(9):979‑86.

34. Wuertz C, Gilbert P, Baier W, Kunz C. Cross-sectional study of factors that influence the 25-hydroxyvitamin D status in pregnant women and in cord blood in Germany. Br J Nutr. nov 2013;110(10):1895‑902.

514 35. Saraf R, Morton SMB, Camargo CA, Grant CC. Global summary of maternal and
515 newborn vitamin D status - a systematic review. Matern Child Nutr. 2016;12(4):647‑68.
516 36. Karras SN, Shah I, Petroczi A, Goulis DG, Bili H, Papadopoulou F, et al. An
517 observational study reveals that neonatal vitamin D is primarily determined by maternal
518 contributions: implications of a new assay on the roles of vitamin D forms. Nutr J. 7 juin
519 2013;12:77.
520 37. Välimäki V-V, Löyttyniemi E, Pekkarinen T, Välimäki MJ. How well are the optimal
521 serum 25OHD concentrations reached in high-dose intermittent vitamin D therapy? a placebo-
522 controlled study on comparison between 100 000 IU and 200 000 IU of oral D3 every 3
523 months in elderly women. Clin Endocrinol (Oxf). juin 2016;84(6):837‑44.
524 38. Gellert S, Ströhle A, Bitterlich N, Hahn A. Higher prevalence of vitamin D deficiency
525 in German pregnant women compared to non-pregnant women. Arch Gynecol Obstet. juill
526 2017;296(1):43‑51.
527 39. Richard A, Rohrmann S, Quack Lötscher KC. Prevalence of Vitamin D Deficiency
528 and Its Associations with Skin Color in Pregnant Women in the First Trimester in a Sample
529 from Switzerland. Nutrients. 10 mars 2017;9(3).
530 40. Perez-Ferre N, Torrejon MJ, Fuentes M, Fernandez MD, Ramos A, Bordiu E, et al.
531 Association of low serum 25-hydroxyvitamin D levels in pregnancy with glucose homeostasis
532 and obstetric and newborn outcomes. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin
533 Endocrinol. oct 2012;18(5):676‑84.
534 41. Fernández-Alonso AM, Dionis-Sánchez EC, Chedraui P, González-Salmerón MD,
535 Pérez-López FR, Spanish Vitamin D and Women's Health Research Group. First-trimester
536 maternal serum 25-hydroxyvitamin D_3 status and pregnancy outcome. Int J Gynaecol Obstet
537 Off Organ Int Fed Gynaecol Obstet. janv 2012;116(1):6‑9.
538 42. Sempos CT, Vesper HW, Phinney KW, Thienpont LM, Coates PM, Vitamin D
539 Standardization Program (VDSP). Vitamin D status as an international issue: national surveys
540 and the problem of standardization. Scand J Clin Lab Investig Suppl. 2012;243:32‑40.
541
542

	n	Mean ± SD or n (% of patients)
Age at inclusion (years)	2803	31.5±5.0
Age ≥35 (years)		734 (26.2%)
Gestational age at inclusion (GW)	2803	10.8±0.8
BMI before the beginning of pregnancy (kg/m^2)	2773	23.5±4.6
BMI ≥25 (kg/m^2)		861 (31.1%)
Pre gestational diabetes mellitus	2778	103 (3.7%)
Season of conception	2803	
Summer		712 (25.4%)
Fall		692 (24.7%)
Winter		704 (25.1%)
Spring		695 (24.8%)
Phototype*	2803	
Types 1 to 4		2191 (78.2%)
Types 5 and 6		612 (21.8%)
Parity**	2781	
0		1349 (48.5%)
1		966 (34.7%)
>1		466 (16.8%)
Smoking		
Before the ongoing pregnancy	2760	569 (20.6%)
Active at the beginning of pregnancy	2743	317 (11.6%)
Active at inclusion	2727	225 (8.2%)
Vitamin D supplementation during the month before inclusion	2452	74 (3.0%)
Vitamin D supplementation in 7th month***	2592	2296 (88.6%)

Table 1. Characteristics of the population.

548 BMI: body mass index, GW: gestational weeks, n: number of patients with available data, SD:
549 standard deviation. *According to the Fitzpatrick phototyping scale, **excluding the ongoing
550 pregnancy, *** vitamin D supplementation in 7th month of pregnancy consists of 100,000 IU
551 cholecalciferol, according to the French guidelines.

552
553

		1st trimester	3rd trimester	Cord blood
	n	**2762**	**2327**	**1763**
Gestational age (GW)	**Mean ± SD [Min-Max]**	10.8±0.8 [6.6-12.9]	33.4±2.4 [23.9-39.9]	37.6±1.5 [25.4-40.7]
Serum 25(OH)D (ng/mL)	**Mean ± SD [Min-Max]**	21.9±10.4 [3.0-78.0]	31.8±11.5 [1.0-99.0]	17.0±7.2 [3.0-54.0]
25(OH)D categories n (%)	**<10 ng/mL**	286 (10.4%)	29 (1.2%)	231 (13.1%)
	10-20 ng/mL	998 (36.1%)	297 (12.8%)	977 (55.4%)
	20-30 ng/mL	829 (30.0%)	703 (30.2%)	439 (24.9%)
	≥30 ng/mL	649 (23.5%)	1298 (55.8%)	116 (6.6%)

554
555 **Table 2.** Serum 25(OH)-vitamin D during pregnancy and at cord blood.
556 n: number of patients, SD: standard deviation, Min: minimum, Max: maximum, 25(OH)D:
557 25(OH)-vitamin D, GW: gestational weeks.
558

559

	1st trimester			3rd trimester			Cord blood		
	25(OH)D (ng/mL)			25(OH)D (ng/mL)			25(OH)D (ng/mL)		
	<20 n=1284	≥20 n=1478	P value	<20 n=326	≥20 n=2001	P value	<20 n=1208	≥20 n=555	P value
Age (years)			0.029			0.017			0.18
<35	973 (75.8)	1066 (72.1)		256 (78.5)	1445 (72.2)		913 (75.6)	403 (72.6)	
≥35	311 (24.2)	412 (27.9)		70 (21.5)	556 (27.8)		295 (24.4)	152 (27.4)	
BMI (kg/m^2)			<0.001			0.012			<0.001
<25	827 (65.3)	1056 (72.0)		205 (63.3)	1401 (70.2)		797 (66.4)	420 (75.8	
≥25	439 (34.7)	411 (28.0)		119 (36.7)	594 (29.8)		403 (33.6)	134 (24.2)	
Phototype*			<0.001			<0.001			<0.001
1 to 4	901 (70.2)	1259 (85.2)		209 (64.1)	1657 (82.8)		931 (77.1)	483 (87.0)	
5 and 6	383 (29.8)	219 (14.8)		117 (35.9)	344 (17.2)		277 (22.9)	72 (13.0)	
Parity**			0.026			0.002			0.062
0	587 (46.2)	741 (50.4)		135 (41.5)	1015 (50.7)		573 (47.5)	290 (52.2)	
≥1	684 (53.8)	728 (49.6)		190 (58.5)	985 (9.3)		634 (52.5)	265 (47.8)	
Smoking***			0.41			0.64			1
no	1112 (89.0)	1277 (87.9)		287 (89.4)	1750 (88.5)		1050 (88.2)	484 (88.2)	
yes	138 (11.0)	175 (12.1)		34 (10.6)	227 (11.5)		141 (11.8)	65 (11.8)	
Season**			<0.001			0.014			<0.001
Summer	160 (12.5)	455 (30.8)		59 (18.2)	529 (26.5)		245 (20.3)	207 (37.3)	
Fall	305 (23.7)	416 (28.2)		103 (31.7)	595 (29.7)		326 (27.0)	154 (27.7)	
Winter	394 (30.7)	274 (18.5)		70 (21.5)	366 (18.3)		284 (23.5)	82 (14.8)	
Spring	425 (31.1)	333 (22.5)		93 (28.6)	510 (25.5)		353 (29.2)	112 (20.2)	
Vitamin D before inclusion¥			<0.001						
no	1101 (99.1)	1245 (95.2)		NA	NA		NA	NA	

yes	10 (0.9)	63 (4.8)		NA	NA		NA	NA	
Vitamin D in 7th month¥¥						<0.001			0.20
no				74 (23.8)	148 (7.6)		119 (10.2)	44 (8.2)	
yes				237 (76.2)	1802 (92.4)		1052 (89.8)	493 (91.8)	
Previous 25(OH)D¥¥¥						<0.001			<0.001
≥30 ng/mL				28 (8.7)	530 (26.9)		436 (39.7)	450 (88.7)	
20-30 ng/mL				77 (24.1)	624 (31.7)		456 (41.5)	43 (8.5)	
10-20 ng/mL				136 (42.5)	664 (33.7)		190 (17.3)	12 (2.4)	
<10 ng/mL				79 (24.7)	151 (7.7)		17 (1.5)	2 (0.4)	

Table 3. Univariate analysis of the determinants of severe vitamin D insufficiency (defined as serum 25(OH)-vitamin D <20 ng/mL) during pregnancy and in cord blood.

BMI: body mass index, 25(OH)D: serum 25(OH)-vitamin D concentration, NA: non-applicable. *According to the Fitzpatrick phototyping scale,**excluding the ongoing pregnancy,***active at the beginning of pregnancy, ****season of sampling, ¥vitamin D supplementation during the month before inclusion, ¥¥vitamin D supplementation in 7th month of pregnancy (cholecalciferol, 100,000 IU), ¥¥¥ serum 25(OH)D concentrations at the previous visit (for the third trimester, the previous visit took place in the first trimester; for cord blood, the previous visit took place in the third trimester. Results are shown as n (%).

		3rd trimester			Cord blood		
	Supplementation*	**No**	**Yes**	**P value**	**No**	**Yes**	**p value**
	n	222	2039		163	1545	
Serum 25(OH)D (ng/mL)	**Mean ± SD**	25.8±11.1	32.5±11.4	<0.001	15.5±7.1	17.2±7.22	0.004
25(OH)D categories n (%)	**<10 ng/mL**	12 (5.4%)	16 (0.8%)	<0.001	33 (20.2%)	191 (12.4%)	0.03
	10-20 ng/mL	62 (27.9%)	221 (10.8%)		86 (52.8%)	861 (55.7%)	
	20-30 ng/mL	68 (30.6%)	616 (30.2%)		37 (22.7%)	388 (25.1%)	
	≥30 ng/mL	80 (36.1%)	1186 (58.2%)		7 (4.3%)	105 (6.8%)	

577 **Table 4.** Serum 25(OH)-vitamin D at the third trimester and in cord blood for subjects who
578 were and who were not supplemented as recommended by the French guidelines in the 7th
579 month of pregnancy (cholecalciferol, 100,000 IU)*.
580 n: number of subjects, SD: standard deviation, 25(OH)D: 25(OH)-vitamin D.

	1st trimester		3rd trimester		Cord blood	
	OR [95% CI]	**p value**	**OR [95% CI]**	**p value**	**OR [95% CI]**	**p value**
Age (years)						
<35			1.00			
≥35			0.66 [0.48-0.91]	0.01		
BMI (kg/m²)						
<25	1.00				1.00	
≥25	1.33 [1.10-1.61]	0.003			1.32 [1.00-1.73]	0.049
Phototype*						
1-4	1.00		1.00			
5-6	2.70 [2.17-3.36]	<0.001	1.80 [1.34-2.40]	<0.001		
Parity**						
0			1			
≥1			1.47 [1.12-1.92]	0.005		
Season***						
Summer	1.00		1.00		1.00	
Fall	2.03 [1.57-2.63]	<0.001	1.86 [1.27-2.72]	0.002	2.18 [1.59-2.99]	<0.001
Winter	4.43 [3.41-5.76]	<0.001	4.04 [2.62-6.23]	<0.001	3.15 [2.19-4.51]	<0.001
Spring	4.16 [3.22-5.38]	<0.001	2.24 [1.51-3.31]	<0.001	1.96 [1.39-2.75]	<0.001
Vitamin D before inclusion¥			NA	NA	NA	NA
no	1.00		NA	NA	NA	NA
yes	0.16 [0.08-0.31]	<0.001	NA	NA	NA	NA

Vitamin D in 7th month¥¥	NA	NA				
no			1.00			
yes			0.21 [0.15-0.29]	<0.001		
Previous 25(OH)D¥¥¥	NA	NA				
≥30	NA	NA	1.00		1.00	
20-30	NA	NA	2.83 [1.77-4.53]	<0.001	10.59 [7.49-14.98]	<0.001
10-20	NA	NA	4.71 [2.98-7.47]	<0.001	16.26 [8.89-29.74]	<0.001
<10	NA	NA	13.84 [8.18-23.43]	<0.001	7.66 [1.73-33.90]§	0.007

Table 5. Multivariate analysis of the determinants of severe vitamin D insufficiency (defined as serum 25(OH)-vitamin D<20 ng/mL) during pregnancy and in cord blood.

BMI: body mass index, 25(OH)D: serum 25(OH)-vitamin D concentration, NA: non-applicable. *According to the Fitzpatrick phototyping scale,**excluding the ongoing pregnancy, ***season at the time of sampling, ¥vitamin D supplementation during the month before inclusion, ¥¥vitamin D supplementation in 7th month of pregnancy (cholecalciferol, 100,000 IU), ¥ ¥¥ serum 25(OH)D concentrations at the previous visit (for the third trimester, the previous visit took place at the first trimester; for cord blood, the previous visit took place at the third trimester), §among women with 25(OH)D below 10 ng/mL at the third trimester, only two had 25(OH)D above 20 ng/mL in cord blood.

Country	Latitude	n	Pregnancy		Cord Blood	Method for 25(OH)D measurement
			Timing of sampling	25(OH)D concentrations (ng/mL), and by category when available (%)	25(OH)D concentrations (ng/mL), and by category when available (%)	
Finland (29)	60°N	584	T1 GW 6–13	Mean ±SD 35.5±7.6 -1%<20 ng/mL	Mean ±SD 35.3 ± 8.8 -1%<20 ng/mL	CLIA
south-western Sweden GraviD study (27)	57-58°N	1985	T1 before GW 17	Mean ±SD 25.8±9.8 - 25% <20 ng/L - 10% <12 ng/mL	NO	LC-MS/MS
		1836	T3 after GW 31	Mean ±SD 29.8±13.8		
Scotland (20)	57°N	1205 (T1 and cord blood)	T2 GW 19	Mean (95%CI) 16.0 (15.4-16.7) - 21·5%<10 ng/mL	Mean (95%CI) 8.7 (8.2-9.4) - 50 % <10 ng/mL	LC-MS/MS
Denmark (28)	54-57°N	1494	T2 GW 25	Mean ±SD 22.7±9.8 - 76.9% <.30 ng/ml - 42.3% < 20 ng/ml - 10.1% < 10 ng/ml	NO	LC-MS/MS
North West of England (30)	53°N	- Mother: 608 - CB: 345	T2/T3 26.9 GW (range 26.0-28.7)	Median (IQR) 30.6 (19.2–38.1) -27% <20 ng/mL -7% <10 ng/mL	Median (IQR) - 15.4 (9.8–22.4) - 65% <20 ng/mL - 26% <10 ng/mL	LC-MS/MS
Ireland SCOPE study (21)	52°N	1768	T2 GW 15 (range, 14-16)	Mean ±SD 22.7±10.4 - 75% <30 ng/mL - 44% <20 ng/mL - 11% <10 ng/mL	NO	LC–MS/MS
Ireland SCOPE study (22)	52°N	1050			Mean ±SD 14.0±7.2 - 80% <20 ng/mL - 35% (50% during winter) <10 ng/mL	LC–MS/MS

Belgium (26)	49-51°N	640	T1	Median 20.4	NO	RIA
		666	T3	Median 22.7		
		1311	T1+ T3 (+5 patients at T2)	- 74.1% <30 ng/mL - 44.6% <20 ng/mL - 12.1% <10 ng/mL		
Germany (34)	47-54°N	- Mother: 261 - CB: 328	delivery or within 72 h post-partum	Median (IQR) 10.0 (5.0–18.2) -77% <20 ng/mL	Median (IQR) 13.6 (7·1–23.4) - 69% <20 ng/mL	CLIA
Germany (38)	47-54°N	429	between the 2nd and 41st GW (mean±SD: 23.8 ±11.5)	Mean ±SD 14.2± 8	NO	CLIA
Switzerland (39)	47°N	204	7 GW	63% <20 ng/mL	NO	CLIA
		n=75 Vit ≥20 ng/ml	7 GW	Mean (95%CI) 26.1 (24.8–27.4)		
		n=129 Vit <20 ng/ml	7 GW	Mean (95%CI) 10.5 (9.7–11.5)		

Table 6: Vitamin D status during pregnancy and in cord blood reported in studies from northern Europe (countries with latitudes equal or higher than the one reported in the present study: 47-49°N). Studies are presented according to the latitude of the country (higher to lower latitudes). Results from the countries of southern Europe are not mentioned in this table since it was the purpose of a review by Karras et al published in 2016 (33).

CLIA: chemiluminescence immunoassay, LC-MS/MS: chromatography tandem-mass spectrometry, RIA: Radioimmunoassay, GW: gestational weeks, T1: first trimester, T2: second trimester, T3: third trimester, CB: cord blood, SD: standard deviation, IQR: interquartile range, CI: confidence interval, 25(OH)D: serum 25(OH)-vitamin D concentration, n: number of patients.